CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices
News Aug 03, 2012
CEVEC Pharmaceuticals and Paragon Bioservices, Inc. have announced a joint collaboration earlier whereby Paragon Bioservices would license and use CEVEC's know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.
"We are very pleased to be working with Paragon Bioservices," said Wolfgang Kintzel, CEVEC's CEO. "Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large."
Paragon's CEO, Marco Chacón, PhD, agrees, "Even though our upstream developmental team has many years of experience in cell biology and bioprocess development, this is a highly competitive business. Everyone needs an edge to meet the outsourcing challenges of our clients. This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods. We look forward to a long relationship with CEVEC."
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Mechanism by Which Alpha Synuclein Causes Cell Death in Parkinson's IdentifiedNews
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.READ MORE